Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

NEXT STORY
Cenobamate Designated Promising Innovative Medicine (PIM) by the UK’s MHRA for Treatment of Drug-Resistant Focal-Onset Seizures in Adults
PREV STORY
Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Nerve Conduit Market to Reach USD 450 Million by 2028; Use of Nerve Conduit Bridging Technique to Generate Revenue, States Vantage Market Research

author_avatar
NASDAQ Market News

PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer

author_avatar
NASDAQ Market News

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

author_avatar
NASDAQ Market News